January 2022
BANDIT trial filled
Thanks to the generosity of the type 1 diabetes community, we have completed recruitment for the BANDIT trial.
Achievements
December 2023
Research breakthrough
In a world-first, ATIC researchers lead by Professor’s Thomas Kay and Helen Thomas have shown that baricitinib, an immunotherapy treatment commonly used in rheumatoid arthritis, can delay the progression of type 1 diabetes...
AchievementsPage last updated: 21 November 2023